Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Recurso digital |
| Lenguaje: | |
| Publicado: |
Zenodo
2026
|
| Materias: | |
| Acceso en línea: | https://doi.org/10.5281/zenodo.20174453 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1866901755087814656 |
|---|---|
| author | Mulla Samir Ismail*, Sunil Dangre |
| author_facet | Mulla Samir Ismail*, Sunil Dangre |
| contents | <p class="MsoNormal"><span>Liver cancer, particularly hepatocellular carcinoma (HCC), remains a leading cause of cancer-related mortality worldwide due to late-stage diagnosis and limited treatment options. Early detection plays a crucial role in improving patient survival and therapeutic outcomes. The use of biomarkers—measurable biological indicators—offers a promising, non-invasive strategy for identifying liver cancer at its earliest stages. Traditional biomarkers such as alpha-fetoprotein (AFP) have long been used but show limited sensitivity and specificity. Recent advances in molecular biology have introduced novel biomarkers including des-gamma- carboxy prothrombin (DCP), Golgi protein 73 (GP73), glypican-3 (GPC3), and circulating microRNAs (e.g., miR-21, miR-122), which demonstrate greater diagnostic accuracy. Integrating multiple biomarkers through advanced detection techniques such as liquid biopsy, proteomics, and genomic profiling enhances the reliability of early diagnosis.<span> </span>Approach not only facilitates timely intervention but also supports personalized treatment and better prognosis. Therefore, the use of biomarker-based screening represents a significant advancement toward early detection and effective management of liver cancer.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_20174453 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | A Review on Biomarkers for Early Detection of Liver Cancer Mulla Samir Ismail*, Sunil Dangre Hepatocellular Carcinoma (HCC),Early Detection of Cancer,Biomarkers, Tumor / analysis,Alpha- Fetoproteins (AFP),Des-Gamma-Carboxy Prothrombin (DCP),Glypican-3 (GPC3),MicroRNAs / blood,Circulating Tumor DNA (ctDNA),Liquid Biopsy,Proteomics,Genomics <p class="MsoNormal"><span>Liver cancer, particularly hepatocellular carcinoma (HCC), remains a leading cause of cancer-related mortality worldwide due to late-stage diagnosis and limited treatment options. Early detection plays a crucial role in improving patient survival and therapeutic outcomes. The use of biomarkers—measurable biological indicators—offers a promising, non-invasive strategy for identifying liver cancer at its earliest stages. Traditional biomarkers such as alpha-fetoprotein (AFP) have long been used but show limited sensitivity and specificity. Recent advances in molecular biology have introduced novel biomarkers including des-gamma- carboxy prothrombin (DCP), Golgi protein 73 (GP73), glypican-3 (GPC3), and circulating microRNAs (e.g., miR-21, miR-122), which demonstrate greater diagnostic accuracy. Integrating multiple biomarkers through advanced detection techniques such as liquid biopsy, proteomics, and genomic profiling enhances the reliability of early diagnosis.<span> </span>Approach not only facilitates timely intervention but also supports personalized treatment and better prognosis. Therefore, the use of biomarker-based screening represents a significant advancement toward early detection and effective management of liver cancer.</span></p> |
| title | A Review on Biomarkers for Early Detection of Liver Cancer |
| topic | Hepatocellular Carcinoma (HCC),Early Detection of Cancer,Biomarkers, Tumor / analysis,Alpha- Fetoproteins (AFP),Des-Gamma-Carboxy Prothrombin (DCP),Glypican-3 (GPC3),MicroRNAs / blood,Circulating Tumor DNA (ctDNA),Liquid Biopsy,Proteomics,Genomics |
| url | https://doi.org/10.5281/zenodo.20174453 |